Marshall Wace, LLP Infla Rx N.V. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Infla Rx N.V. stock. As of the latest transaction made, Marshall Wace, LLP holds 307,082 shares of IFRX stock, worth $408,419. This represents 0.0% of its overall portfolio holdings.
Number of Shares
307,082Holding current value
$408,419% of portfolio
0.0%Shares
7 transactions
Others Institutions Holding IFRX
# of Institutions
31Shares Held
19.2MCall Options Held
52KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY6.48MShares$8.62 Million0.25% of portfolio
-
Bank Of America Corp Charlotte, NC2.48MShares$3.29 Million0.0% of portfolio
-
683 Capital Management, LLC New York, NY2.25MShares$2.99 Million0.17% of portfolio
-
Ra Capital Management, L.P. Boston, MA1.97MShares$2.62 Million0.04% of portfolio
-
Eversept Partners, LP New York, NY1.73MShares$2.3 Million0.18% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $58.8M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...